Atrás
Rango del Día
$27.86
$29.47
Rango de 52 Semanas
$9.60
$30.58
Volumen
2,125,168
Promedio 50D / 200D
$25.21
/
$21.69
Cierre Anterior
$27.89
Quick Summary
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Healthcare (631 pares)
| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -16.1 | 0.3 |
| P/B | 9.5 | 3.0 |
| ROE % | -73.9 | 3.7 |
| Net Margin % | — | 3.8 |
| Rev Growth 5Y % | — | 10.0 |
| D/E | 0.3 | 0.2 |
Precio Objetivo de Analistas
Hold
$38.60
+36.8%
Low: $35.00
High: $42.00
EPS Futuro
-$1.64
Ingresos Est.
2.25M
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2029 |
$0.32
$0.32 – $0.32
|
451.57M | 4 |
| FY2028 |
-$1.14
-$2.88 – $1.20
|
166.89M | 11 |
| FY2027 |
-$1.73
-$2.32 – -$1.13
|
22.52M | 13 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2025-11-05 | -$0.39 | -$0.41 | -5.1% |
| 2025-08-12 | -$0.35 | -$0.38 | -8.6% |
| 2025-05-14 | -$0.35 | -$0.20 | +42.9% |
| 2025-03-24 | -$0.38 | -$0.34 | +10.5% |
| 2024-11-12 | -$0.42 | -$0.37 | +11.9% |
| 2024-08-13 | -$0.38 | -$0.40 | -5.3% |
| 2024-05-13 | -$0.41 | -$0.38 | +7.3% |
| 2024-03-28 | -$0.44 | -$0.38 | +13.6% |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 2, 2026 |
Bush Tia L
Chief Technology & Quality Ofc
|
grant | 175,000 | — | — |
| Feb 1, 2026 |
Bush Tia L
Chief Technology & Quality Ofc
|
other | 8,549 | $24.57 | $210,048.93 |
| Dec 8, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 10,000 | $9.53 | — |
| Dec 8, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
sell | 10,000 | $30.00 | $300,000.00 |
| Nov 17, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 12,000 | $5.84 | — |
| Nov 17, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 6,000 | $27.64 | $165,835.20 |
| Nov 1, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 593 | $24.90 | $14,765.70 |
| Sep 10, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 40,000 | $5.84 | — |
| Sep 10, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 20,000 | $22.00 | $440,000.00 |
| Sep 9, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 40,000 | $5.84 | — |
| Sep 9, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 20,000 | $20.01 | $400,102.00 |
| Aug 1, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 597 | $17.17 | $10,250.49 |
| Jul 29, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
sell | 8,322 | $15.23 | $126,750.72 |
| Jul 25, 2025 |
Weinhoff Gregory M
Chief Business Officer
|
other | 20,000 | $3.85 | — |
| Jul 25, 2025 |
Weinhoff Gregory M
Chief Business Officer
|
sell | 10,000 | $15.56 | $155,598.00 |
| Jul 21, 2025 |
SAHA SAURABH
Chief Executive Officer
|
other | 110,000 | $3.85 | — |
| Jul 21, 2025 |
SAHA SAURABH
Chief Executive Officer
|
sell | 55,000 | $15.92 | $875,600.00 |
| Jul 15, 2025 |
HUSSAIN IQBAL J
General Counsel
|
other | 12,000 | $5.84 | — |
| Jul 15, 2025 |
HUSSAIN IQBAL J
General Counsel
|
sell | 6,000 | $14.93 | $89,566.80 |
| Jun 24, 2025 |
Accardi Mario Alberto
President, Orexin Program
|
other | 30,000 | $3.85 | — |
Dividend History
Yield
0.00%
Payout Ratio
0.00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Puntos Clave
Debt/Equity of 0.29 — conservative balance sheet
Negative free cash flow of -142.09M
Crecimiento
Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
-73.93%
ROIC-29.07%
Net MarginN/A
Op. MarginN/A
Seguridad
Debt / Equity
0.29
Current Ratio9.25
Interest Coverage-19.93
Valoración
P/E Ratio
-16.09
Forward P/EN/A
P/B Ratio9.45
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -100.00% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -235.76M |
| ROE | -73.93% | ROA | -40.87% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -142.09M |
| ROIC | -29.07% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.29 | Current Ratio | 9.25 |
| Interest Coverage | -19.93 | ||
| Dividends | |||
| Dividend Yield | 0.00% | Payout Ratio | 0.00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -16.09 | Forward P/E | N/A |
| P/B Ratio | 9.45 | P/S Ratio | N/A |
| PEG Ratio | -0.26 | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | 2618.16 |
| Forward P/S | 1689.35 | Fwd Earnings Yield | N/A |
| FCF Yield | -3.75% | ||
| Market Cap | 3.79B | Enterprise Value | 3.53B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 6.85M | 0.0 | 0.0 | 0.0 |
| Net Income | -235.76M | -151.09M | -216.21M | -381.90M | -10.66M |
| EPS (Diluted) | -2.06 | -1.57 | -2.31 | -4.24 | -0.08 |
| Gross Profit | 0.0 | 6.85M | 0.0 | 0.0 | 0.0 |
| Operating Income | -201.06M | -171.28M | -212.26M | -374.87M | -10.44M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 576.80M | 360.25M | 444.31M | 629.64M | 11.72M |
| Total Liabilities | 175.25M | 124.00M | 108.14M | 138.08M | 8.62M |
| Shareholders' Equity | 401.55M | 236.24M | 336.17M | 491.55M | 3.10M |
| Total Debt | 117.23M | 84.59M | 69.80M | 75.70M | 5.63M |
| Cash & Equivalents | 383.22M | 128.03M | 393.64M | 595.08M | 7.23M |
| Current Assets | 536.41M | 315.09M | 437.75M | 628.77M | 11.17M |
| Current Liabilities | 58.00M | 39.39M | 38.34M | 24.64M | 8.62M |